Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $332000.0.

  • Biodesix's Gains from Investment Securities fell 9173.92% to $332000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $332000.0, marking a year-over-year decrease of 9173.92%. This contributed to the annual value of $4.2 million for FY2024, which is 10396.86% up from last year.
  • Latest data reveals that Biodesix reported Gains from Investment Securities of $332000.0 as of Q3 2025, which was down 9173.92% from $6.9 million recorded in Q2 2025.
  • Biodesix's 5-year Gains from Investment Securities high stood at $6.9 million for Q2 2025, and its period low was -$58000.0 during Q4 2023.
  • In the last 5 years, Biodesix's Gains from Investment Securities had a median value of $2.8 million in 2022 and averaged $2.3 million.
  • Per our database at Business Quant, Biodesix's Gains from Investment Securities tumbled by 12396.69% in 2023 and then soared by 93620.69% in 2024.
  • Quarter analysis of 5 years shows Biodesix's Gains from Investment Securities stood at $2.9 million in 2021, then tumbled by 91.56% to $242000.0 in 2022, then plummeted by 123.97% to -$58000.0 in 2023, then surged by 936.21% to $485000.0 in 2024, then tumbled by 31.55% to $332000.0 in 2025.
  • Its Gains from Investment Securities stands at $332000.0 for Q3 2025, versus $6.9 million for Q2 2025 and $378000.0 for Q1 2025.